Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis registers COPD drug NDA in Japan
NVA237 is a long-acting muscarinic antagonist (LAMA) used to treat adult patients with chronic obstructive pulmonary disease (COPD). In April 2005, Novartis licensed the drug from Japan’s Sosei
NVA237 is a long-acting muscarinic antagonist (LAMA) used to treat adult patients with chronic obstructive pulmonary disease (COPD). In April 2005, Novartis licensed the drug from Japan’s Sosei
Immunicum’s vaccine is based on using dendritic cells from healthy individuals and can be mass-produced, leading to commercial advantages, the company said. The study will be conducted on
LAPS-rhGH is currently being evaluated under phase II trial in patients with growth hormone deficiency in European countries. According to the company, the orphan drug designation would be
The company has been charged with, by the US Department of Justice, adulteration and mislabeling of its products, besides violation of current Good Manufacturing Practice (cGMP) regulations. ATF
AMR101 is a prescription-grade omega-3 fatty acid, consisting at least 96% ultra pure EPA (icosapent ethyl). The NDA for AMR101 is backed by data from the two Phase
PharmAust is a unit of Epichem that contributed cash to the university to gain an additional 11% in the JV, proactiveinvestors.com.au reported. It is believed that the treatment
The pre-clinical study compared the use of aerosolised IFN-beta against placebo as either a pre-infection protective measure or as a post-infection treatment measure. The study also reported that
According to the company, the new center, , which is worth CHF250m ($271m), will take the responsibility for investigation and development of pharmaceutical formulations for new active ingredients,
The new system will be used effectively from mid-January 2012 by all the MR and MA of Chugai. A wide range of information is provided to medical professionals,
The Drugs of Abuse Array V (DoA V) will enable detection of eight designer drugs and their metabolites within a single undivided specimen. The panel targets Methcathinone, Mephedrone,